Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-002324-16-CZ (EUCTR)	13/06/2014	08/01/2014	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
2	EUCTR2013-002324-16-PL (EUCTR)	04/06/2014	09/04/2014	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
3	NCT02038049 (ClinicalTrials.gov)	December 20, 2013	14/1/2014	A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis	A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis	Relapse Remitting Multiple Sclerosis	Drug: VAY736;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	55 Years	All	8	Phase 2	United States;Czechia;Ukraine;Czech Republic;Germany;Poland;Russian Federation